Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
38,346,880
-
Total 13F shares
-
29,583,750
-
Share change
-
-652,891
-
Total reported value
-
$198,790,015
-
Put/Call ratio
-
0%
-
Price per share
-
$6.72
-
Number of holders
-
105
-
Value change
-
-$4,881,405
-
Number of buys
-
66
-
Number of sells
-
48
Institutional Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) as of Q2 2025
As of 30 Jun 2025,
Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) was held by
105 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,583,750 shares.
The largest 10 holders included
BAKER BROS. ADVISORS LP, MPM ASSET MANAGEMENT LLC, 5AM Venture Management, LLC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock, Inc., VANGUARD GROUP INC, JANUS HENDERSON GROUP PLC, WELLINGTON MANAGEMENT GROUP LLP, StepStone Group LP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
105
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.